Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
Alkermes (NASDAQ:ALKS) Given New $43.00 Price Target at Cantor Fitzgerald
Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...
Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on October 25. Uy Ear has given his ...
Nasdaq13d
Alkermes's Earnings: A Preview
Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
ETF Daily News10d
Alkermes (NASDAQ:ALKS) Rating Reiterated by Piper Sandler
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
Alkermes: Strong Buy Rating Amidst Short-term Challenges and Long-term Growth Potential
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...
PR Newswire13d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...
Zacks.com on MSN13d
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures ...